Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1358427 | 0.89 | PPARD (0.50) | PPARDLPAR3LPAR1LPAR2TSHR | |
| SCHEMBL2170863 | 0.87 | PPARD (0.43) | PPARDLPAR3LPAR1LPAR2TSHR | |
| Ammonia Solution, Strong SCHEMBL7040273 | 0.87 | PPARD (0.48) | PPARDTSHRALDH1A1 | |
| SCHEMBL20672347 | 0.86 | PPARD (0.44) | PPARDLPAR3LPAR1LPAR2TSHR | |
| SCHEMBL4246781 | 0.84 | MEN1 (0.38) | PPARDLPAR3LPAR1LPAR2TSHR | |
| SCHEMBL2350370 | 0.80 | PPARD (0.38) | PPARDTSHRMEN1KMT2A | |
| SCHEMBL2355386 | 0.80 | GABBR2 (0.47) | PPARDTSHRCYP3A4MEN1KMT2A | |
| SCHEMBL5485187 | 0.80 | CYP3A4 (0.56) | LPAR3LPAR1LPAR2TSHRCYP3A4 | |
| SCHEMBL26980275 | 0.80 | PPARD (0.56) | PPARDLPAR3LPAR1LPAR2TSHR | |
| SCHEMBL1359596 | 0.79 | CYP3A4 (0.50) | PPARDLPAR3LPAR1LPAR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379571-A1 | METHOD FOR THE PRODUCTION OF MIXED-SUBSTITUTED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | Clariant International Ltd. (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-20110245386-A1 | Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-06 | — | — | US | disclosed |
| WO-2010069419-A1 | METHOD FOR THE PRODUCTION OF MIXED-SUBSTITUTED DIALKYLPHOSPHINIC ACIDS, ESTERS, AND SALTS, AND USE THEREOF | CLARIANT INTERNATIONAL LTD (CH) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245386-A1 | Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof | HAO2, ACSL3, SCO2 | PPARD 2351/4885LPAR3 138/4885LPAR1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.